$AVCO holding steady in this market downturn...ver
Post# of 46475
![](/assets/46931549/no_avatar_available_thumb.jpg)
“Given our rapid progress this past year, our goal for 2022 is to focus on our core programs to drive innovation and bring about advanced technologies and new medicines to patients. Towards this end, we have decided not to move ahead with the SenlangBio acquisition. Instead, we plan to focus our resources on organic growth and strategic partnership opportunities that we believe will hold the potential to drive much greater value for our shareholders, while avoiding potentially significant dilution that would have occurred with the proposed acquisition.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)